Several studies have identified c-FLIP as an independent adverse indicator in cancer and found both c-FLIPL and c-FLIPS play important roles in cancer patient treatment outcomes and that the expression of particular c-FLIP isoforms has prognostic clinical value [66,78–86]. This evidence concerns the gene CFLAR and cancer.